Marketing Regulation

We provide legal advice to domestic and overseas pharmaceutical companies, medical device manufacturers, bio-venture companies, research insutitute such as universities and contract research organizations (CROs) and other various clients. We have extensive experience advising on licenses, filing and other requirements for the Marketing Authorization Holder (MAH) and the sellers of drugs and medical devices, and drafting and reviewing documents for such bisinesses.

Contact us

PublicationsArchives

2023.11.28
Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.08.24
Thematic-based: Legal Practice in the Healthcare Business
2022.07.04
China's Life Sciences and Healthcare-No.2 -The Good Vigilance Practice rule in China
2022.05.26
Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.03.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the
2022.02.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the
2022.01.21
Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
2021.11.24
Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) - Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft
2021.10.28
Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) -Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)

MORE

SeminarsArchives

MORE

ページTOPへ